Response to anti-VEGF treatments shown to associate with specific genetic sequences

Injection of ranibizumab (Lucentis) or bevacizumab (Avastin) are currently the standard treatment for neovascular AMD however, the response to treatment can vary among patients. Advance knowledge regarding which patients are most likely to respond positively may contribute to improved clinical management. Recent clinical studies reported by the Institute of Medical Molecular Genetics, University of Zurich and the Department of Ophthalmology, University Hospital of Zurich, Switzerland, demonstrate that responders to anti-VEGF treatments may be grouped in reference to specific genetic associations.